Table 1 Cohort clinical and pathologic characteristics
| Â | Current clonal dynamics | Remaining patients | P value |
|---|---|---|---|
Study cohort | In phase II study | ||
Age | 0.67 | ||
 Median | 52 | 49 | |
 Range | 42–69 | 31–78 | |
Stage at diagnosis of primary breast cancer | 0.74 | ||
 I | 1 (14%) | 5 (17%) | |
 II | 4 (57%) | 15 (50%) | |
 III | 1 (14%) | 7 (23%) | |
 Iv | 1 (14%) | 1 (3%) | |
Germline BRCA status | 0.97 | ||
 Wildtype | 6 (86%) | 20 (71%) | |
 Mutant | 1 (14%) | 4 (14%) | |
 Unkown | 0 (0%) | 4 (14%) | |
Primary cancer receptor status | 0.25 | ||
 Triple negative | 5 (72%) | 23 (82%) | |
Metastatic biopsy receptor status | 1 | ||
 Triple negative | 7 (100%) | 28 (100%) | |
Metastatic site | |||
 Lung metastases | 1 (14%) | 13 (46%) | 0.1 |
 Liver metastases | 4 (57%) | 7 (25%) | 0.11 |
 Bone metastases | 5 (71%) | 12 (43%) | 0.17 |
Neoadjuvant therapy | 0.24 | ||
 Recieved | 7 (100%) | 19 (68%) | |
Prior lines of metastatic therapy | 0.44 | ||
 0 | 1 (14%) | 5 (18%) | |
 1 | 4 (57%) | 14 (50%) | |
 2 | 1 (14%) | 3 (11%) | |
 3+ | 1 (14%) | 6 (21%) | |